+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 1Year +
All Genders
ID07203001

Open-label Phase II Study of MAS825 to Assess Efficacy and Safety in Pediatric and Adult Patients With Stills Disease

Led by Novartis Pharmaceuticals · Updated on 2026-09-25

30

Participants Needed

23

Research Sites

55 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating MAS825 arumakimig in a phase II trial to study its clinical efficacy, safety, and tolerability in both pediatric and adult participants with Stills disease. This trial includes individuals who have had an inadequate response to IL-1, IL-6, or other available therapies. Participants with associated lung disease or macrophage activation syndrome may also join the study, which lasts approximately 16 months across multiple centers. Participants receive MAS825 in an open-label, single-arm design with no placebo group. The study consists of three periods Screening, Treatment Period 1, and Treatment Period 2. The treatment aims to assess response based on clinical criteria and biomarker levels. The drug is administered under medical supervision, and participants are monitored throughout the trial. During the study, participants undergo various assessments including clinical response evaluations on Day 85, biomarker measurements, physician assessments, and quality of life questionnaires. The study also tracks changes in glucocorticoid dose and disease activity over up to 15 months. Safety and tolerability are closely monitored, and the total participation time spans about 16 months from screening through treatment and follow-up.

CONDITIONS

Brief Title

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here